Truist Raises Madrigal Pharmaceuticals Price Target to $743 From $709
Truist kept its Buy rating on Madrigal Pharmaceuticals.
Related stories
Advantage Solutions Reports Q3 Results, Announces Restructuring
Advantage Solutions reported revenue of $913.7 million and a net loss of $25.1 million for the quarter ended September 30, 2026. Its restructuring is expected to deliver about $25
M impact | EQUITY | Nov 04, 2026, 02:15 PM UTC
InnovAge Reports Fiscal Q1 2027 Revenue of $264.8 Million
Revenue rose 12.1% year over year and income before taxes increased 153.1% to $20.0 million. Diluted EPS was $0.14 versus analyst expectations of $0.09. Fiscal 2027 revenue guidanc
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Solid Power Reports Q3 2026 Results, Cuts Cash Investment Outlook
Solid Power reported third-quarter revenue and grant income of $1.2 million and a net loss of $24.4 million, or $0.11 per share. It lowered its 2026 cash investment outlook to $75
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Shoals Technologies Reports Q3 Revenue of $195.3 Million, Raises 2026 Outlook
Revenue rose 43.8% year over year to $195.3 million, and adjusted EBITDA reached $39.8 million, above the company’s expected range. Shoals guided to fiscal 2026 revenue of $665 mil
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Taboola Reports Q3 Revenue of $462.3 Million, Issues Q4 Guidance
Taboola reported Q3 revenue of $462.3 million, below a FactSet estimate of $466.3 million. Adjusted EBITDA rose 16.1% to $56.0 million, and net income increased to $18.4 million fr
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Flowco Reports Third-Quarter 2026 Revenue of $258.6 Million
Flowco reported net income of $40.7 million, adjusted EBITDA of $103.9 million and free cash flow of $72.4 million. Diluted EPS was $0.40, above the FactSet consensus estimate of $
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC